These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 29688429)

  • 1. EF24 (a Curcumin Analog) and ZSTK474 Emphasize the Effect of Cabozantinib in Medullary Thyroid Cancer.
    Bertazza L; Sensi F; Cavedon E; Watutantrige-Fernando S; Censi S; Manso J; Vianello F; Casal Ide E; Iacobone M; Pezzani R; Mian C; Barollo S
    Endocrinology; 2018 Jun; 159(6):2348-2360. PubMed ID: 29688429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.
    Bertazza L; Barollo S; Radu CM; Cavedon E; Simioni P; Faggian D; Plebani M; Pelizzo MR; Rubin B; Boscaro M; Pezzani R; Mian C
    J Cell Mol Med; 2015 Sep; 19(9):2244-52. PubMed ID: 26081844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological Effects of EF24, a Curcumin Derivative, Alone or Combined with Mitotane in Adrenocortical Tumor Cell Lines.
    Bertazza L; Barollo S; Mari ME; Faccio I; Zorzan M; Redaelli M; Rubin B; Armanini D; Mian C; Pezzani R
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31212829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
    Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
    Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy.
    Thomas SL; Zhao J; Li Z; Lou B; Du Y; Purcell J; Snyder JP; Khuri FR; Liotta D; Fu H
    Biochem Pharmacol; 2010 Nov; 80(9):1309-16. PubMed ID: 20615389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
    Verbeek HH; Alves MM; de Groot JW; Osinga J; Plukker JT; Links TP; Hofstra RM
    J Clin Endocrinol Metab; 2011 Jun; 96(6):E991-5. PubMed ID: 21470995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. XL184 (cabozantinib) for medullary thyroid carcinoma.
    Durante C; Russo D; Verrienti A; Filetti S
    Expert Opin Investig Drugs; 2011 Mar; 20(3):407-413. PubMed ID: 21314233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies.
    Bisht S; Schlesinger M; Rupp A; Schubert R; Nolting J; Wenzel J; Holdenrieder S; Brossart P; Bendas G; Feldmann G
    J Nanobiotechnology; 2016 Jul; 14(1):57. PubMed ID: 27401816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curcumin analog EF24 induces apoptosis via ROS-dependent mitochondrial dysfunction in human colorectal cancer cells.
    He G; Feng C; Vinothkumar R; Chen W; Dai X; Chen X; Ye Q; Qiu C; Zhou H; Wang Y; Liang G; Xie Y; Wu W
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1151-1161. PubMed ID: 27787644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.
    Carra S; Gaudenzi G; Dicitore A; Saronni D; Cantone MC; Plebani A; Ghilardi A; Borghi MO; Hofland LJ; Persani L; Vitale G
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
    Kumarasamy VM; Sun D
    Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
    Kurzrock R; Sherman SI; Ball DW; Forastiere AA; Cohen RB; Mehra R; Pfister DG; Cohen EE; Janisch L; Nauling F; Hong DS; Ng CS; Ye L; Gagel RF; Frye J; Müller T; Ratain MJ; Salgia R
    J Clin Oncol; 2011 Jul; 29(19):2660-6. PubMed ID: 21606412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple anticancer activities of EF24, a novel curcumin analog, on human ovarian carcinoma cells.
    Tan X; Sidell N; Mancini A; Huang RP; Shenming Wang ; Horowitz IR; Liotta DC; Taylor RN; Wieser F
    Reprod Sci; 2010 Oct; 17(10):931-40. PubMed ID: 20693500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
    Krajewska J; Olczyk T; Jarzab B
    Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1.
    Thomas SL; Zhong D; Zhou W; Malik S; Liotta D; Snyder JP; Hamel E; Giannakakou P
    Cell Cycle; 2008 Aug; 7(15):2409-17. PubMed ID: 18682687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog.
    Liu H; Liang Y; Wang L; Tian L; Song R; Han T; Pan S; Liu L
    PLoS One; 2012; 7(10):e48075. PubMed ID: 23118928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell lines.
    Dicitore A; Grassi ES; Caraglia M; Borghi MO; Gaudenzi G; Hofland LJ; Persani L; Vitale G
    Endocrine; 2016 Jan; 51(1):101-12. PubMed ID: 25863490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-33b, upregulated by EF24, a curcumin analog, suppresses the epithelial-to-mesenchymal transition (EMT) and migratory potential of melanoma cells by targeting HMGA2.
    Zhang P; Bai H; Liu G; Wang H; Chen F; Zhang B; Zeng P; Wu C; Peng C; Huang C; Song Y; Song E
    Toxicol Lett; 2015 May; 234(3):151-61. PubMed ID: 25725129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
    Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
    J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octreotide and pasireotide effects on medullary thyroid carcinoma (MTC) cells growth, migration and invasion.
    Giardino E; Catalano R; Mangili F; Barbieri AM; Treppiedi D; Elli FM; Dolci A; Contarino A; Spada A; Arosio M; Mantovani G; Peverelli E
    Mol Cell Endocrinol; 2021 Jan; 520():111092. PubMed ID: 33248230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.